A Phase 3 interventional study of Oxymetazoline Hydrochloride and Rhofade Cream, 1% in Rosacea, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-23.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.
Among the 145 studies in Rosacea with a site in United States, this one is the 3rd largest by enrollment of the 137 interventional ones that give a count, is one of 9 that started in 2019, is one of 32 in phase 3, and was the 110th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Narrows Institute for Biomedical Research · Sites in United States
Ages 18+ · Healthy volunteers
University of Miami · Sites in United States
Ages 18+
Wright State University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 34 · Phase 4 20
First in 2002; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,105 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 78 across the 137 interventional studies, 236 across the 8 observational. Of the 127 that completed or were terminated, 76 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 145 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 5 studies filed under Rosacea — fewer than ten, so there is no comparison to draw.
3 of the studies in Rosacea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07443202Tarsus Pharmaceuticals, Inc.Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | 2026-12-31 |
| NCT06801717University of MiamiRosacea Radiofrequency Microneedling | 2027-07-01 |
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 145 studies in Rosacea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxymetazoline hydrochloride cream, 1%
Drug: Oxymetazoline Hydrochloride
RHOFADE Cream, 1%
Drug: Rhofade Cream, 1%
Vehicle cream
Drug: Placebo
Test Comparator
Reference Comparator
Also known as: Oxymetazoline hydrochloride
Placebo Comparator
Also known as: Oxymetazoline hydrochloride
Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician Erythema Assessment Score at Least 2 Grades Lower Than the Baseline (Day 1 Predose) Value
The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).
Time frame: 29 days
| Milestone | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream |
|---|---|---|---|
| Started | 379 | 382 | 344 |
| Completed | 366 | 366 | 327 |
| Not completed | 13 | 16 | 17 |
| Withdrew: Withdrawal by subject | 5 | 5 | 5 |
| Withdrew: Adverse event | 1 | 3 | 2 |
| Withdrew: Protocol violation | 0 | 3 | 5 |
| Withdrew: Use of prohibited therapy | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Non-compliant with study drug application | 2 | 2 | 0 |
| Withdrew: Administrative reasons | 0 | 0 | 1 |
| Withdrew: Miscellaneous | 3 | 2 | 1 |
The primary efficacy endpoint was the proportion of subjects with treatment success at all time points 3, 6, 9, and 12 hours post-application on Day 29. Treatment success was defined as having CEA score at least 2 grades lower than the baseline (Day 1 pre-dose) value. Clinician Erythema Assessment was measured as (0-clear, 1-almost clear, 2-mild, 3-moderate, 4- severe).
| Participants | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream |
|---|---|---|---|
| Success | 78 | 70 | 51 |
| Failure | 271 | 286 | 265 |
Collected over 2 month adverse event data collection. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxymetazoline Hydrochloride Cream, 1% | 0/379 (0%) | 0/379 (0%) | 61/379 (16.1%) |
| RHOFADE Cream, 1% | 0/382 (0%) | 1/382 (0.3%) | 60/382 (15.7%) |
| Vehicle Cream | 0/344 (0%) | 1/344 (0.3%) | 48/344 (14%) |
| Event | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream |
|---|---|---|---|
| Clavicle fractureInjury, poisoning and procedural complications | 0/379 | 0/382 | 1/344 |
| Acute myocardial infarctionCardiac disorders | 0/379 | 1/382 | 0/344 |
| Event | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream |
|---|---|---|---|
| Application site painGeneral disorders | 9/379 | 16/382 | 10/344 |
| Application site pruritusGeneral disorders | 14/379 | 16/382 | 7/344 |
| HeadacheNervous system disorders | 9/379 | 11/382 | 12/344 |
| Application site erythemaGeneral disorders | 7/379 | 10/382 | 7/344 |
| Application site reactionGeneral disorders | 8/379 | 2/382 | 1/344 |
| Application site acneGeneral disorders | 4/379 | 6/382 | 2/344 |
| Application site drynessGeneral disorders | 5/379 | 2/382 | 1/344 |
| Upper respiratory tract infectionInfections and infestations | 0/379 | 0/382 | 3/344 |
| Application site dermatitisGeneral disorders | 3/379 | 2/382 | 1/344 |
| AcneSkin and subcutaneous tissue disorders | 3/379 | 0/382 | 0/344 |
Safety Population also defined as in the Participant Flow
| Age, Continuous(years) | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 46.9 ± 13.87 | 46.2 ± 14.01 | 47.2 ± 14.50 | 46.8 ± 14.11 |
| Sex: Female, Male(Participants) | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream | Total |
|---|---|---|---|---|
| Female | 282 | 284 | 258 | 824 |
| Male | 97 | 98 | 86 | 281 |
| Ethnicity (NIH/OMB)(Participants) | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream | Total |
|---|---|---|---|---|
| Hispanic or Latino | 202 | 205 | 182 | 589 |
| Not Hispanic or Latino | 177 | 177 | 162 | 516 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 9 | 2 | 4 | 15 |
| White | 369 | 377 | 337 | 1083 |
| More than one race | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Clinical Erythema Assessment Score(Participants) | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream | Total |
|---|---|---|---|---|
| 0-Clear | 0 | 0 | 0 | 0 |
| 1-Almost Clear | 0 | 0 | 0 | 0 |
| 2-Mild | 0 | 0 | 0 | 0 |
| 3-Moderate | 287 | 292 | 273 | 852 |
| 4-Severe | 92 | 90 | 71 | 253 |
| Baseline Subject Self-Assessment(Participants) | Oxymetazoline Hydrochloride Cream, 1% | RHOFADE Cream, 1% | Vehicle Cream | Total |
|---|---|---|---|---|
| 0-No Sign | 0 | 0 | 0 | 0 |
| 1-Almost Clear | 0 | 0 | 0 | 0 |
| 2-Mild | 0 | 0 | 0 | 0 |
| 3-Moderate | 282 | 287 | 261 | 830 |
| 4-Severe | 97 | 95 | 83 | 275 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Jan 2020, 8 months.
Results were first posted in Jun 2021, 1 year 5 months after primary completion.
Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxymetazoline